Children and adolescents: patients
≥10 and ≥18 years of age.
Childhood T2DM: disease in the child who typically: is obese (BMI ≥85th to 94th percentile and >95th percentile for age and gen- der, respectively); has a strong family history of T2DM; has sub- stantial residual insulin secretory capacity at diagnosis (reflected by normal or elevated insulin and C- peptide concentrations); has insidi- ous onset of disease; demonstrates insulin resistance (including clinical evidence of polycystic ovarian syn- drome or acanthosis nigricans); and lacks evidence of diabetic auto- immunity. These patients are more likely to have hypertension and dys- lipidemia than those with T1DM.
Hyperglycemia: definition as ac- cepted by the ADA. Specifically: fast- ing blood glucose (BG) concentration >126 mg/dL, random or 2-hour post- Glucola (Ames Co, Elkhart, IN) BG concentration >200 mg/dL.
Clinician: any provider within his or her scope of practice; includes med- ical practitioners (including physi- cians and physician extenders), dietitians, psychologists, and nurses.
Comorbidities: specifically limited to cardiovascular disease (CVD), hyper- tension, dyslipidemias and hypercholes- terolemias, atherosclerosis, peripheral neuropathy, retinopathy, and nephro- pathy (microvascular and macrovas- cular). Obesity was considered a prediabetic condition and was specif- ically excluded.